CymaBay Therapeutics Inc.


By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

Contact Information

Main Phone: +1 510 293-8800
Address: 7575 Gateway Boulevard
Address 2: Suite 110
State: CA
City / Town: Newark
Country: US
Postal Code: 94560

Issuer Information

Exchange: NGS
CEO: Sujal Shah
Employees: 41
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A